Shire Pharmaceuticals has
announced the US$4.2 billion
purchase of ViroPharma, with the
move “entirely consistent with
our clear strategic objective of
strengthening our rare disease
portfolio,” according to Shire ceo
Flemming Ornskov.
ViroPharma products include
Cinryze (C1 esterase inhibitor)
which is approved for the
prophylactic treatment of
hereditary angiodema (HAE), and
will complement Shire’s Firazyr
(icatibant) for the same condition.
ViroPharma’s revenue last year
was US$428m, with Shire saying
it sees “significant opportunity for
future revenue growth” for Cinryze,
both in the US and overseas
markets as new HAE patients are
identified and more doctors gain
experience with the therapy.The above article was sent to subscribers in Pharmacy Daily's issue from 13 Nov 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Nov 13
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.